Programmed death-1 receptor (PD-1) and its
ligand (PD-L1) play an integral role in regulating the immune response against
cancer. This study investigated the prognostic significance of PD-L1 expression on
tumor cells and
tumor-infiltrating immune cells (TILs) in the tumor microenvironment in Chinese patients with
esophageal squamous cell carcinoma (ESCC). Archival
formalin-fixed,
paraffin-embedded ESCC samples from treatment-naïve patients with ESCC after surgery or by diagnostic endoscopic biopsy were collected between 2004 and 2014. Expression of PD-L1 in ESCC
tumor specimens was assessed by immunohistochemistry (IHC), and the degree of TIL infiltration was evaluated by examining
hematoxylin and
eosin-stained (H&E) specimens. PD-L1+ as defined as ≥1% of
tumor cell membranes showing ≥1+ intensity. In 428 patients, specimens from 341 (79.7%) were PD-L1+. In the definitive treatment group (patients who received curative
esophagectomy or definitive [chemo-]
radiation therapy), PD-L1 positivity was associated with a significantly shorter DFS and OS. In the palliative
chemotherapy group exhibited, neither PFS nor OS correlated significantly with PD-L1 expression. PD-L1 expression was positively associated with TIL density. In 17 paired
tumor tissues collected before and
after treatment, an increase in PD-L1 expression was associated with
disease progression, whereas a decrease in PD-L1 expression was associated with response to
chemotherapy or disease control. So, PD-L1 expression was associated with a significantly worse prognosis in patients with ESCC. These observations suggest that PD-L1 may play a critical role in ESCC
cancer progression and provide a rationale for developing
PD-L1 inhibitors for treatment of a subset of ESCC patients.